¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low dose tolerance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´ç³»¼º°Ë»ç
  • oxygen tolerance
    »ê¼Ò³»¼º
  • self-tolerance
    1. ÀÚ°¡°ü¿ë 2. ÀÚ°¡³»¼º
  • low back pain
    Ç㸮ÅëÁõ, ¿äÅë
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ
  • low cervical cesarean section
    ¾Æ·¡ÀڱøñÁ¦¿ÕÀý°³(¼ú), ÇϺÎÀڱðæºÎÁ¦¿ÕÀý°³(¼ú)
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹éÁú
  • low echo area
    ³·Àº¸Þ¾Æ¸®¿µ¿ª, Àú¿¡ÄÚ¿µ¿ª
  • low fever
    ¹Ì¿­
  • low field magnetic resonance scanner
    ÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • low forceps delivery
    ÀúÀ§Áý°ÔºÐ¸¸(¼ú), ÀúÀ§°âÀںи¸(¼ú)
  • low frequency deafness
    ÀúÁ֯ij­Ã»
  • low grade glioma
    Àúµî±Þ±³Á¾
  • low potency
    1. ÀúÈ¿´É, Àú¿ª°¡ 2. ÀúÀáÀç·Â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • radiation dose
    ¹æ»ç¼±·®
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • high-dose
    °í¿ë·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low fever
    ¹Ì¿­
  • low-output heart failure
    Àú¹ÚÃâ½ÉÀåºÎÀü
  • low-pass filter
    ÀúÅë°ú°Å¸£°³, ÀúÅë°ú¿©°ú±â
  • low grade glioma
    ¾ç¼º½Å°æ¾Æ±³Á¾
  • low-tension glaucoma
    Àú¾È¾Ð³ì³»Àå
  • low pressure hydrocephalus
    Àú¾Ð¹°³úÁõ, Àú¾Ð¼öµÎÁõ
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ
  • low signal intensity
    Àú½ÅÈ£°­µµ
  • low signal
    Àú½ÅÈ£, ³·Àº½ÅÈ£
  • low back pain
    ¿äÅë
  • low cervical cesarean section
    ¾Æ·¡ÀڱøñÁ¦¿ÕÀý°³¼ú, ÇϺÎÀڱðæºÎÁ¦¿ÕÀý°³¼ú
  • low field magnetic resonance scanner
    ÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • low temperature resin
    Àú¿Â¼öÁö
  • low-ionic-strength salt solution
    ÀúÀ̿°­µµ¿°¿ë¾×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fructose tolerance test
    ÇÁ¶ôÅ佺ºÎÇϽÃÇè.
  • fructose tolerance test
    ÇÁ¶ôÅ佺ºÎÇϽÃÇè
  • galactose tolerance test
    °¥¶ôÅ佺ºÎÇÏ ½ÃÇè.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • glucose tolerance
    ³»´ç·Â(Ò±ÓØæ³).
  • glucose tolerance test
    ´çºÎÇϽÃÇè
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
  • heat tolerance
    ³»¿­¼º(Ò±æðàõ).
  • heat tolerance
    ³»¿­¼º(ËÀËçËÛ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º½ÃÇè.
  • high-zone tolerance
    °í¿ª°ü¿ë, Ç׿ø°ú·®°ü¿ë
  • immune tolerance
    ¸é¿ª°ü¿ë
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • acceleration tolerance
    °¡¼Ó³»¼º(Ê¥áÜ Ò±àõ)
  • acquired tolerance
    ȹµæ°ü¿ë, ÈÄõ¼º°ü¿ë
  • acquired tolerance
    ÈÄõ(¼º) ³»¼º(¡­Ò±àõ), ȹµæ°ü¿ë.
  • adoptive tolerance
    ÀÔ¾ç(¸é¿ª)°ü¿ë(ìýåרóæ¹Î°é»).
  • alcohol tolerance
    ¾ËÄڿ󻼺(¡­Ò±àõ).
  • alkali tolerance
    ¾ËÄ®¸®³»¼º(¡­Ò±àõ)
  • altimeter tolerance
    ³»°í¼Ò¼º(ËÀË­ËÛËÛ).
  • antigen tolerance
    Ç׿ø°ü¿ë.
  • autoimmune disease,immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • autoimmune disease,tolerance
    ³»¿ë·Â(Ò®é»æ³)
  • carbohydrate tolerance
    ź¼öÈ­¹°ºÎÇÏ(¡­Ý¶ùÃ), ź¼öÈ­¹°³»Àμº.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low background counter
    ³·Àº¹ÙÅÁ °è¼ö±â(ͪâ¦Ðï)
  • low-copy number
    Àú(î¸)Ä«ÇǼö(â¦)
  • low-density fraction
    Àú¹ÐµµºÐȹ(î¸ÚËÓøÝÂüñ)
  • low-density lipoprotein
    Àú¹Ðµµ Áö´Ü¹éÁú(î¸ÚËÓøò·Ó±ÛÜòõ)
  • low-energy compound
    Àú(î¸)¿¡³ÊÁöÈ­ÇÕ¹°(ûùùêÚª)
  • low-energy electron diffraction
    Àú(î¸)¿¡³ÊÁö ÀüÀÚȸÀý(ï³í­üÞï¹)
  • low-energy ion scattering
    Àú(î¸)¿¡³ÊÁö À̿ºлê(ÝÂߤ)
  • low-energy phophate acceptor
    Àú(î¸)¿¡³ÊÁö Àλê¼ö³³Ã¼(×òß«áôÒ¡ô÷)
  • low-frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ(î¸ÞºÓøû¡òõÓôìý)
  • low-level promoter
    ÀúÀ§(î¸êÈ) ÇÁ·Î¸ðÅÍ
  • low-lipid lipoprotein
    ÀúÁöÁú Áö´Ü¹éÁú(î¸ò·òõò·Ó±ÛÜòõ)
  • low-order antibody
    ÀúÂ÷Ç×ü(î¸ó­ù÷ô÷)
  • low-potential iron protein
    ÀúÀüÀ§ ö´Ü¹éÁú(î¸ï³êÈôÑÓ±ÛÜòõ)
  • low-quality protein
    ÀúÁú´Ü¹éÁú(î¸òõÓ±ÛÜòõ)
  • low-speed sedimentaion equilibrium
    Àú¼Óħ°­ÆòÇü(î¸áÜöØË½øÁû¬)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • curative dose
    ġȿ·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose rate
    ¼±·®·ü
  • fatal dose
    Ä¡»ç·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AITT arginine insulin tolerance test; augmented insulin tolerance test
ATT arginine tolerance test; aspirin tolerance time
ETT endotracheal tube; epinephrine tolerance test; exercise tolerance test; exercise treadmill test; ext...
LTT lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te...
LF labile factor; lactoferrin; laryngofissure; Lassa fever; latex fixation; left foot; left forearm; le...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LDRI low dose rate irradiation
ETT Exercise Tolerance Test
FTQ Fagerstrom Tolerance Questionnaire
FSIGTT Frequently sampled intravenous glucose tolerance test
GTF Glucose Tolerance Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immunological tolerance
    ¸é¿ª ³»¼º
    ´Ù¸¥ »óÅ¿¡¼­´Â ü¾×¼º ¶Ç´Â ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» À¯¹ßÇÒ ¼ö Àִ ƯÁ¤ÀÇ Ç׿ø¿¡ ´ëÇØ¼­, ¸²ÇÁ°è Á¶Á÷ÀÇ Æ¯ÀÌÀû ¹«¹ÝÀÀ¼ºÀÌ ÀϾµµ·Ï µÇ´Â °ÍÀ» Ư¡ÀûÀ¸·Î ÇÏ´Â ¸é¿ª ¹ÝÀÀ.
  • individual tolerance
    °³Àκ° ³»¼º
    ºñÁ¤»óÀûÀ¸·Î ´ë·®ÀÇ ¾à¹°¿¡ ´ëÇÏ¿© µ¶¿µÇâÀ» ¹ÞÁö ¾Ê°í °ßµð¸ç ¶ÇÇÑ ÀÏÁ¤·®ÀÇ ¾à¹°ÀÇ Áö¼ÓÀûÀÎ »ç¿ë¿¡ ´ëÇØ¼­ È¿°úÀÇ °¨¼Ò¸¦ ³ªÅ¸³»´Â ´É·Â.
  • lactose tolerance test
    ¶ôÅä¿À½º ³»¼º ½ÃÇè
  • median tolerance limit
    ¹Ý¼ö »ýÁ¸ ÇÑ°è ³óµµ
  • pain tolerance
    µ¿Åë ³»¼º, ÅëÁõ ³»¼º
    ÂüÀ» ¼ö ÀÖ´Â ÅëÁõÀÇ °¡Àå Å« ¼öÁØ.
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º
  • poison tolerance
    µ¶¹° ³»¼º
    Áö¼ÓÀûÀÎ µ¶¼º ¹°Áú¿¡ ÀÇÇØ »ýü°¡ ±× µ¶¼º ¹°Áú¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °Í.
  • tolerance
    ³»¾à¼º, ³»¼º, ³»¿ë·Â, Çã¿ë, °ü¿ë
    1. º¸Åë ¾à¹°À̳ª µ¶¹°ÀÇ ¸¹Àº »ç¿ë·®À» °ßµð¾î ³¾ ¼ö ÀÖ´Â ´É·Â. 2. ÈÄõÀûÀ¸·Î ȹµæµÈ ¾à¹° ³»¼º. ¹Ýº¹ÀûÀÎ µ¿·®ÀÇ »ç¿ë·®¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÇ °¨¼Ò ȤÀº °°Àº ¹ÝÀÀÀ» ¾ò±â À§Çؼ­ Áõ°¡µÈ »ç¿ë·®À» ¿ä±¸ÇÏ´Â °Í.
  • tolerance span
    Àγ» ±â°£
  • tolerance to antimicrobial
    Ç×±ÕÁ¦ ³»¼º
  • tolerance to high altitude
    °í¼Ò ³»¼º
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ì Áõ»ó
    ¼ö¸éº´ ȯÀÚ¿¡°Ô¼­ º¼ ¼ö ÀÖ´Â ¼³ ÁøÀü.
  • low
    ³·Àº, Àú
  • low birth weight
    ÀúüÁß Ãâ»ý
  • low carat gold alloy
    ÀúÄ«¶óÆ® ±Ý ÇÕ±Ý
    16Ä«¶óÆ® ÀÌÇÏÀÇ ±Ý ÇÕ±Ý. ³³Âø ÇÕ±ÝÀ» ¸»ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
self tolerance The normal lack of the ability to produce an immunological response to autologous (self) antigens. A breakdown of self tolerance leads to autoimmune diseases. The ability to recognise the difference between self and non-self is the prime function of the immune system.
(12 Dec 1998)
species tolerance The insensitivity to a particular drug exhibited by a particular species.
(05 Mar 2000)
split tolerance Modification of an immune response to an antigen after prior exposure to that antigen.
Synonym: split tolerance.
(05 Mar 2000)
nonresponder tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
immune tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (foetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
(12 Dec 1998)
immunological tolerance <immunology> Specific unresponsiveness to antigen. Self tolerance is a process occurring normally early in life due to suppression of self reactive lymphocyte clones.
Tolerance to foreign antigens can be induced in adult life by exposure to antigens under conditions in which specific clones are suppressed. Note that tolerance is not the same as immunological unresponsiveness, since the latter may be very non-specific as in immunodeficiency states.
(18 Nov 1997)
immunologic tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
impaired glucose tolerance Blood glucose (sugar) levels higher than normal but not high enough to be called diabetes. People with impaired glucose tolerance may or may not develop diabetes.
Other names (no longer used) for impaired glucose tolerance are borderline, subclinical, chemical, or latent diabetes.
(30 Mar 1998)
individual tolerance Tolerance to a drug that the person has never received before.
(05 Mar 2000)
oral lactose tolerance test A test for lactose deficiency; the plasma glucose response to an oral lactose load is measured as in the (oral) glucose tolerance test.
(05 Mar 2000)
test, glucose tolerance After fasting, a specific amount (100 grams) of glucose is given by mouth, and the blood levels of this sugar are measured every hour. Normally, the blood glucose should return to normal within 2 to 2 1/2 hours. The gtt is considered a classic test of carbohydrate metabolism. It is much used in the diagnosis of diabetes. The gtt depends on a number of factors including the ability of the intestine to absorb glucose, the power of the liver to take up and store glucose, the capacity of the pancreas to produce insulin, and the amount of active insulin.
(12 Dec 1998)
tolerance 1. The ability to endure unusually large doses of a drug or toxin.
2. Acquired drug tolerance, a decreasing response to repeated constant doses of a drug or the need for increasing doses to maintain a constant response.
Origin: L. Tolerantia
(18 Nov 1997)
exercise tolerance The exercise capacity of an individual as measured by endurance (maximal exercise duration and/or maximal attained work load) during an exercise test.
(12 Dec 1998)
frustration tolerance The level of an individual's ability to withstand frustration without developing inadequate modes of response, such as "going to pieces" emotionally.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low
    ³·°Ô;³·Àº °÷¿¡;¾ßºñ(õ)ÇϰÔ;½Î°Ô;°Ë¼ÒÇÑ À½½ÄÀ¸·Î;Àûµµ °¡±îÀÌ;~ down ÈξÀ ¾Æ·¡¿¡;Ǫ´ëÁ¢ÇÏ¿©
  • low
    ³·Àº °Í;Àú¼Ó±â¾î;Àú±â¾Ð
  • low
    ¼ÒÀÇ ¿ïÀ½¼Ò¸®
  • low
    (¼Ò µûÀ§°¡) ¿ò¸ÅÇÏ°í ¿ï´Ù;±½Àº ¸ñ¼Ò¸®·Î ¸»ÇÏ´Ù
  • low comedy
    Àú¼ÓÇÑ Äڹ̵ð !
  • low frequency
    ÀúÁÖÆÄ
  • low relief
    ¾èÀº µ¸À»»õ±è
  • low tea
    °£´ÜÇÑ ½Ä»ç
  • low tide
    °£Á¶;½ä¹°
  • low water
    °£Á¶;ÃÖÀú¼ö¸é
  • new low
    X;»õ·Î¿î ÃÖÀú °¡°Ý;ÃÖÀú±â·Ï(cf.NEW HIGH)
  • very low frequency
    ÃÊÀåÆÄ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á